Study details
Enrolling now
Lemborexant for Sleep in Epilepsy
University of Manitoba
NCT IDNCT06262594ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
26
Study length
about 2.5 years
Ages
18+
Locations
1 site in NC
What this study is about
Researchers are testing if Lemborexant, a medication, improves sleep in adults with epilepsy. The trial will last 901 days and involve approximately 26 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lemborexant
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
lemborexant
Drug routes
oral (Oral Tablet)
Body systems
Neurology